Compare Summit Therapeutics Inc (SMMT) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Toronto-Dominion Bank — how do they compare? Summit Therapeutics Inc trades at $14.58 (market cap $10.48B), while Toronto-Dominion Bank trades at $120.5 (market cap $197.03B). The key difference: Toronto-Dominion Bank is far larger — about 18.8× Summit Therapeutics Inc's market cap, and Toronto-Dominion Bank pays a 2.62% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | TD | |
|---|---|---|
Market Cap | $10.48B | $197.03B |
Sector | Health | Financials |
52-Week High | $29.32 | $124.80 |
52-Week Low | $13.05 | $72.55 |
Enterprise Value | $9.90B | — |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TD stock trades at $120.53, down 2.48% today, with a bearish technical signal despite recent earnings beats. The company reported strong Q1 2026 EPS of $1.74, beating expectations of $1.63, continuing a pattern of positive surprises. Revenue growth remains steady, climbing from $56.3B in 2024 to $61.3B in 2025. Analyst consensus is bullish with a $153 price target, though technical indicators show mixed signals with RSI neutral and ADX suggesting weakening trend strength.
TD presents a compelling value opportunity with a P/E of 20.08 and strong profitability metrics including 23.38% net income margin. However, investors face risks from volatile cash flow patterns and increasing debt-to-asset ratios. The stock's 27% upside to analyst targets and consistent dividend payments provide support, but macroeconomic sensitivity and regulatory scrutiny require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
